CHRNG Gene: Cholinergic Receptor Nicotinic Gamma Subunit

Genetic insights into CHRNG, its role in neuromuscular development, and associated disorders.

Gene Information Card

Symbol CHRNG
Full Name Cholinergic Receptor Nicotinic Gamma Subunit
Gene Type protein coding
Chromosomal Location 2q33.1
NCBI Gene ID 1146 ncbi.nlm.nih.gov/gene/1146
Ensembl ID ENSG00000196876
UniProt ID P07510
OMIM ID 100730
HGNC ID 1966
Aliases ACHRG, CMS1D, MGC33446

Description

The CHRNG gene encodes the gamma subunit of the nicotinic acetylcholine receptor (nAChR), a pentameric ligand-gated ion channel that mediates fast synaptic transmission at the neuromuscular junction. During fetal development, the gamma subunit is expressed in skeletal muscle and is essential for proper neuromuscular synapse formation. Postnatally, its expression is largely replaced by the epsilon subunit (CHRNE). Mutations in CHRNG are associated with autosomal recessive multiple pterygium syndrome (Escobar variant) and lethal multiple pterygium syndrome, characterized by joint contractures, pterygia, and fetal akinesia.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Multiple Pterygium Syndrome, Escobar Variant Loss-of-function mutations in CHRNG lead to reduced or absent gamma subunit, impairing fetal nAChR function and causing neuromuscular development defects. ClinVar, OMIM
Lethal Multiple Pterygium Syndrome Severe loss-of-function mutations (e.g., frameshift, nonsense) result in complete absence of functional fetal nAChR, leading to fetal akinesia and lethality. OMIM, PubMed
Congenital Myasthenic Syndrome (rare) Some CHRNG mutations may contribute to myasthenic phenotypes, though primarily associated with other nAChR subunits. ClinVar, PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Skeletal Muscle 0.0 Not detected (adult)
Fetal Muscle High Developmental expression
Placenta 0.0 Not detected
Brain 0.0 Not detected
Cell Line Expression
Cell Line nTPM Notes
RHABDOMYOSARCOMA (RD) 0.0 No expression in adult cell lines
SK-UT-1 0.0 No expression
C2C12 (mouse myoblast) High Model for fetal muscle development
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.IVS2-2A>G Splice site Rare Loss of function, causes Escobar syndrome
p.Arg87Ter Nonsense Rare Loss of function, lethal phenotype
p.Cys240Tyr Missense Rare Loss of function, disrupts subunit assembly
Mutation functional classification

Loss of Function (LOF)

Most CHRNG mutations are loss-of-function, leading to reduced or absent gamma subunit, impairing fetal nAChR activity.

Gain of Function (GOF)

No gain-of-function mutations reported for CHRNG.

Dominant Negative (DN)

No dominant-negative effects documented; CHRNG mutations are typically recessive.

Gene Ontology (GO)

• acetylcholine-gated monoatomic cation channel activity • integral component of plasma membrane
• chemical synaptic transmission • muscle contraction
• response to acetylcholine

Pathways

• Acetylcholine signaling at neuromuscular junction
• Nicotinic acetylcholine receptor signaling pathway

Protein Summary

The CHRNG protein (UniProt P07510) is a 517-amino acid subunit of the fetal nicotinic acetylcholine receptor (nAChR). It contains four transmembrane domains (M1-M4) and a large extracellular N-terminal domain that contributes to ligand binding. The gamma subunit is essential for the assembly and function of the fetal (α2βγδ) receptor, which is critical for muscle development. In adults, the gamma subunit is replaced by epsilon, forming the adult (α2βδε) receptor. Mutations affecting the gamma subunit disrupt receptor function, leading to neuromuscular disorders.

Related Products

Product name Cat.No. Species Gene ID
CHRNG Knockout HEK293 Cell Line EDJ-KQ4277 Human 1146 Details Get a Quote
CHRNG Knockout HeLa Cell Line EDJ-KQ52910 Human 1146 Details Get a Quote
CHRNG Knockout A-549 Cell Line EDJ-KQ61376 Human 1146 Details Get a Quote
CHRNG Knockout HCT 116 Cell Line EDJ-KQ69872 Human 1146 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: